News stories about Johnson & Johnson (NASDAQ:JNJ
) have been trending somewhat positive on Thursday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.4319621079741 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Johnson & Johnson (JNJ
) traded up 0.33% during mid-day trading on Thursday, reaching $130.18. The company’s stock had a trading volume of 1,406,239 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The company has a market cap of $353.22 billion and a PE ratio of 21.95. The firm’s 50 day moving average is $132.79 and its 200-day moving average is $129.43.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ ) Earning Somewhat Positive Press Coverage, Accern Reports” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Insider Buying and Selling by Quarter for Johnson & Johnson (NASDAQ:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.